{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:02:31Z","timestamp":1748491351797,"version":"3.41.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,28]]},"DOI":"10.7759\/cureus.84941","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:18:00Z","timestamp":1748416680000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Left Ventricular Thrombus: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Momina","family":"Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinnari","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Given  E","family":"Edim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Mazhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hafiza Zanish","family":"Iram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandipkumar S","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin R","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Areeba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14090948","article-title":"Emerging trends in left ventricular thrombus: a comprehensive review of non-ischemic and ischemic cardiopathies, including eosinophilic myocarditis, Chagas cardiomyopathy, amyloidosis, and innovative anticoagulant approaches","volume":"14","author":"Colle B","year":"2024","unstructured":"Colle B, Demeure F, Higny J, et al.. Emerging trends in left ventricular thrombus: a comprehensive review of non-ischemic and ischemic cardiopathies, including eosinophilic myocarditis, Chagas cardiomyopathy, amyloidosis, and innovative anticoagulant approaches. Diagnostics (Basel). 2024, 14:948. 10.3390\/diagnostics14090948","journal-title":"Diagnostics (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2024-324605","article-title":"Advancing clinical management of left ventricular thrombosis: prevention, detection and treatment modalities in the modern era","author":"Zhang Q","year":"2025","unstructured":"Zhang Q, Zheng H, Zhang Z, Xu Y, Zhang W. Advancing clinical management of left ventricular thrombosis: prevention, detection and treatment modalities in the modern era. Heart. 2025, 10.1136\/heartjnl-2024-324605","journal-title":"Heart"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001092","article-title":"Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association","volume":"146","author":"Levine GN","year":"2022","unstructured":"Levine GN, McEvoy JW, Fang JC, et al.. Management of patients at risk for and with left ventricular thrombus: a scientific statement from the American Heart Association. Circulation. 2022, 146:e205-23. 10.1161\/CIR.0000000000001092","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1074248420977567","article-title":"Left ventricular thrombus therapy with direct oral anticoagulants versus vitamin K antagonists: a systematic review and meta-analysis","volume":"26","author":"Saleiro C","year":"2021","unstructured":"Saleiro C, Lopes J, De Campos D, Puga L, Costa M, Gon\u00e7alves L, Teixeira R. Left ventricular thrombus therapy with direct oral anticoagulants versus vitamin K antagonists: a systematic review and meta-analysis. J Cardiovasc Pharmacol Ther. 2021, 26:233-43. 10.1177\/1074248420977567","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euu311","article-title":"Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence","volume":"17","author":"Vrijens B","year":"2015","unstructured":"Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015, 17:514-23. 10.1093\/europace\/euu311","journal-title":"Europace"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-019-01878-x","article-title":"Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism","volume":"48","author":"Giustozzi M","year":"2019","unstructured":"Giustozzi M, Franco L, Vedovati MC, Becattini C, Agnelli G. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism. J Thromb Thrombolysis. 2019, 48:439-53. 10.1007\/s11239-019-01878-x","journal-title":"J Thromb Thrombolysis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.017559","article-title":"Direct oral anticoagulant use: a practical guide to common clinical challenges","volume":"9","author":"Chen A","year":"2020","unstructured":"Chen A, Stecker E, A Warden B. Direct oral anticoagulant use: a practical guide to common clinical challenges. J Am Heart Assoc. 2020, 9:e017559. 10.1161\/JAHA.120.017559","journal-title":"J Am Heart Assoc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-846592","article-title":"Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu","volume":"132","author":"Chen X","year":"2018","unstructured":"Chen X, Jin DY, Stafford DW, Tie JK. Evaluation of oral anticoagulants with vitamin K epoxide reductase in its native milieu. Blood. 2018, 132:1974-84. 10.1182\/blood-2018-05-846592","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6040103","article-title":"Direct-acting oral anticoagulants and their reversal agents\u2014an update","volume":"6","author":"Kustos SA","year":"2019","unstructured":"Kustos SA, Fasinu PS. Direct-acting oral anticoagulants and their reversal agents\u2014an update. Medicines (Basel). 2019, 6:10.3390\/medicines6040103","journal-title":"Medicines (Basel)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12610","article-title":"Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives","volume":"95","author":"G\u00f3mez-Outes A","year":"2015","unstructured":"G\u00f3mez-Outes A, Su\u00e1rez-Gea ML, Lecumberri R, Terleira-Fern\u00e1ndez AI, Vargas-Castrill\u00f3n E. Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. Eur J Haematol. 2015, 95:389-404. 10.1111\/ejh.12610","journal-title":"Eur J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-024-00585-9","article-title":"Comparative effectiveness and safety of DOACs vs. VKAs in treatment of left ventricular thrombus- a meta-analysis update","volume":"22","author":"Hu T","year":"2024","unstructured":"Hu T, Chen C, Maduray K, Han W, Chen T, Zhong J. Comparative effectiveness and safety of DOACs vs. VKAs in treatment of left ventricular thrombus- a meta-analysis update. Thromb J. 2024, 22:23. 10.1186\/s12959-024-00585-9","journal-title":"Thromb J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02547-7","article-title":"Oral anticoagulation in patients with left ventricular thrombus: a systematic review and network meta-analysis with reconstructed time-to-event data","author":"Heyne S","year":"2024","unstructured":"Heyne S, Macherey-Meyer S, Meertens MM, Finke K, Baldus S, Adler C, Lee S. Oral anticoagulation in patients with left ventricular thrombus: a systematic review and network meta-analysis with reconstructed time-to-event data. Clin Res Cardiol. 2024, 10.1007\/s00392-024-02547-7","journal-title":"Clin Res Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.01.049","article-title":"Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial)","volume":"77","author":"Abdelnabi M","year":"2021","unstructured":"Abdelnabi M, Saleh Y, Fareed A, et al.. Comparative study of oral anticoagulation in left ventricular thrombi (No-LVT Trial). J Am Coll Cardiol. 2021, 77:1590-2. 10.1016\/j.jacc.2021.01.049","journal-title":"J Am Coll Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2024.11.026","article-title":"Direct oral anticoagulants versus Warfarin for the treatment of left ventricular thrombus: a multicenter retrospective observational study","volume":"238","author":"Al-Abcha A","year":"2025","unstructured":"Al-Abcha A, Clay S, Wang L, et al.. Direct oral anticoagulants versus Warfarin for the treatment of left ventricular thrombus: a multicenter retrospective observational study. Am J Cardiol. 2025, 238:21-4. 10.1016\/j.amjcard.2024.11.026","journal-title":"Am J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s43044-021-00164-7","article-title":"Rivaroxaban versus warfarin for the management of left ventricle thrombus","volume":"73","author":"Albabtain MA","year":"2021","unstructured":"Albabtain MA, Alhebaishi Y, Al-Yafi O, et al.. Rivaroxaban versus warfarin for the management of left ventricle thrombus. Egypt Heart J. 2021, 73:41. 10.1186\/s43044-021-00164-7","journal-title":"Egypt Heart J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvab057","article-title":"Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial\u2021","volume":"8","author":"Alcalai R","year":"2022","unstructured":"Alcalai R, Butnaru A, Moravsky G, et al.. Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial\u2021. Eur Heart J Cardiovasc Pharmacother. 2022, 8:660-7. 10.1093\/ehjcvp\/pvab057","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097%2822%2902747-4","article-title":"Direct oral anticoagulants compared with warfarin for the treatment of left ventricular thrombi","volume":"79","author":"Aldaas O","year":"2022","unstructured":"Aldaas O, Ji-Hyun K, Palakodeti S, et al.. Direct oral anticoagulants compared with warfarin for the treatment of left ventricular thrombi. JACC. 2022, 79:1756. 10.1016\/S0735-1097%2822%2902747-4","journal-title":"JACC"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz746.1020","article-title":"P6426 The use of direct oral anti-coagulations (DOACs) compared to vitamin K antagonist in patients with left ventricular thrombus after acute myocardial infarction","volume":"40","author":"Alizadeh M","year":"2019","unstructured":"Alizadeh M, Antoniou S, Fhadil S, et al.. P6426 The use of direct oral anti-coagulations (DOACs) compared to vitamin K antagonist in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J. 2019, 40:746-1020. 10.1093\/eurheartj\/ehz746.1020","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-020-00242-x","article-title":"Direct oral anticoagulant use in left ventricular thrombus","volume":"18","author":"Ali Z","year":"2020","unstructured":"Ali Z, Isom N, Dalia T, Sami F, Mahmood U, Shah Z, Gupta K. Direct oral anticoagulant use in left ventricular thrombus. Thromb J. 2020, 18:29. 10.1186\/s12959-020-00242-x","journal-title":"Thromb J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02371-6","article-title":"Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus","volume":"52","author":"Bass ME","year":"2021","unstructured":"Bass ME, Kiser TH, Page RL 2nd, McIlvennan CK, Allen LA, Wright G, Shakowski C. Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus. J Thromb Thrombolysis. 2021, 52:517-22. 10.1007\/s11239-020-02371-6","journal-title":"J Thromb Thrombolysis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1074248420967644","article-title":"Direct oral anticoagulants in the treatment of left ventricular thrombus: a retrospective, multicenter study and meta-analysis of existing data","volume":"26","author":"Cochran JM","year":"2021","unstructured":"Cochran JM, Jia X, Kaczmarek J, Staggers KA, Rifai MA, Hamzeh IR, Birnbaum Y. Direct oral anticoagulants in the treatment of left ventricular thrombus: a retrospective, multicenter study and meta-analysis of existing data. J Cardiovasc Pharmacol Ther. 2021, 26:173-8. 10.1177\/1074248420967644","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1161\/circ.146.suppl_1.12863","article-title":"Similar rates of embolic and bleeding events for direct oral anticoagulants and warfarin in the treatment of left ventricular thrombus","volume":"146","author":"Conant A","year":"2022","unstructured":"Conant A, Deng Y, Sims DB. Similar rates of embolic and bleeding events for direct oral anticoagulants and warfarin in the treatment of left ventricular thrombus. Circulation. 2022, 146:12863. 10.1161\/circ.146.suppl_1.12863","journal-title":"Circulation"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00898-3","article-title":"Management of left ventricular thrombi with direct oral anticoagulants: retrospective comparative study with vitamin K antagonists","volume":"40","author":"Daher J","year":"2020","unstructured":"Daher J, Da Costa A, Hilaire C, et al.. Management of left ventricular thrombi with direct oral anticoagulants: retrospective comparative study with vitamin K antagonists. Clin Drug Investig. 2020, 40:343-53. 10.1007\/s40261-020-00898-3","journal-title":"Clin Drug Investig"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz747.0118","article-title":"Direct oral anticoagulants are an effective therapy for left ventricular thrombus formation","volume":"40","author":"Gama F","year":"2019","unstructured":"Gama F, Freitas P, Trabulo M, et al.. Direct oral anticoagulants are an effective therapy for left ventricular thrombus formation. Eur Heart J. 2019, 40:459.","journal-title":"Eur Heart J"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2020.05.025","article-title":"Treatment of left ventricular thrombus with direct oral anticoag ulants: a retrospective observational study","volume":"133","author":"Guddeti RR","year":"2020","unstructured":"Guddeti RR, Anwar M, Walters RW, et al.. Treatment of left ventricular thrombus with direct oral anticoag ulants: a retrospective observational study. Am J Med. 2020, 133:1488-91. 10.1016\/j.amjmed.2020.05.025","journal-title":"Am J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-022-00533-w","article-title":"Safety and effectiveness of direct oral anticoagulants versus warfarin for treating left ventricular thrombus","volume":"22","author":"Herald J","year":"2022","unstructured":"Herald J, Goitia J, Duan L, Chen A, Lee MS. Safety and effectiveness of direct oral anticoagulants versus warfarin for treating left ventricular thrombus. Am J Cardiovasc Drugs. 2022, 22:437-44. 10.1007\/s40256-022-00533-w","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12718","article-title":"Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus","volume":"7","author":"Iqbal H","year":"2020","unstructured":"Iqbal H, Straw S, Craven TP, Stirling K, Wheatcroft SB, Witte KK. Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus. ESC Heart Fail. 2020, 7:2032-41. 10.1002\/ehf2.12718","journal-title":"ESC Heart Fail"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4103\/JCPC.JCPC_41_20","article-title":"Apixaban versus warfarin in patients with left ventricular thrombus: a pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus","volume":"9","author":"Isa WY","year":"2020","unstructured":"Isa WY, Hwong N, Yusof AK, Yusof Z, Loong NS, Wan-Arfah N, Naing NN. Apixaban versus warfarin in patients with left ventricular thrombus: a pilot prospective randomized outcome blinded study investigating size reduction or resolution of left ventricular thrombus. J Clin Prev Cardiol. 2020, 9:150-4. 10.4103\/JCPC.JCPC_41_20","journal-title":"J Clin Prev Cardiol"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjca.2018.07.194","article-title":"Treatment of left ventricular thrombus using warfarin versus direct oral anticoagulants following anterior myocardial infarction","volume":"34","author":"Jaidka AK","year":"2018","unstructured":"Jaidka AK, Zhu T, Lavi S, Johri A. Treatment of left ventricular thrombus using warfarin versus direct oral anticoagulants following anterior myocardial infarction. Can J Cardiol. 2018, 34:143.","journal-title":"Can J Cardiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-24-00527","article-title":"Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials","volume":"21","author":"Jenab Y","year":"2025","unstructured":"Jenab Y, Sadeghipour P, Mohseni-Badalabadi R, et al.. Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials. EuroIntervention. 2025, 21:82-92. 10.4244\/EIJ-D-24-00527","journal-title":"EuroIntervention"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvaa096","article-title":"The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction","volume":"7","author":"Jones DA","year":"2021","unstructured":"Jones DA, Wright P, Alizadeh MA, et al.. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021, 7:398-404. 10.1093\/ehjcvp\/pvaa096","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2019.11.056","article-title":"Left ventricular thrombus: patient characteristics and treatment from a single tertiary centre's experience","volume":"297","author":"Lim CW","year":"2019","unstructured":"Lim CW, Mamat RM, Hishammudin IA, et al.. Left ventricular thrombus: patient characteristics and treatment from a single tertiary centre's experience. Int J Cardiol. 2019, 297:20-1. 10.1016\/j.ijcard.2019.11.056","journal-title":"Int J Cardiol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-021-02788-8","article-title":"Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombosis","volume":"16","author":"Mihm AE","year":"2021","unstructured":"Mihm AE, Hicklin HE, Cunha AL, Nisly SA, Davis KA. Direct oral anticoagulants versus warfarin for the treatment of left ventricular thrombosis. Intern Emerg Med. 2021, 16:2313-7. 10.1007\/s11739-021-02788-8","journal-title":"Intern Emerg Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1161\/circ.142.suppl_3.16816","article-title":"Direct oral anticoagulants compared to warfarin for the treatment of left ventricular thrombus: a multi-center experience","volume":"142","author":"Minciunescu A","year":"2020","unstructured":"Minciunescu A, ljaz N, Donthi N, Genovese LD, Tehrani BN, Tran HA. Direct oral anticoagulants compared to warfarin for the treatment of left ventricular thrombus: a multi-center experience. Circulation. 2020, 142:3. 10.1161\/circ.142.suppl_3.16816","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14062129","article-title":"The efficacy and safety of direct oral anticoagulants compared to warfarin for left ventricular thrombus resolution","volume":"14","author":"Paiva MS","year":"2025","unstructured":"Paiva MS, Gama F, Azevedo S, et al.. The efficacy and safety of direct oral anticoagulants compared to warfarin for left ventricular thrombus resolution. J Clin Med. 2025, 14:2129. 10.3390\/jcm14062129","journal-title":"J Clin Med"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2022-002111","article-title":"Improving the management of left ventricular thrombus in a tertiary cardiology centre: a quality improvement project","volume":"12","author":"Rahunathan N","year":"2023","unstructured":"Rahunathan N, Hurdus B, Straw S, Iqbal H, Witte K, Wheatcroft S. Improving the management of left ventricular thrombus in a tertiary cardiology centre: a quality improvement project. BMJ Open Quality. 2023, 12:e002111.","journal-title":"BMJ Open Quality"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.0652","article-title":"Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi","volume":"5","author":"Robinson AA","year":"2020","unstructured":"Robinson AA, Trankle CR, Eubanks G, et al..  Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol. 2020, 5:685-92. 10.1001\/jamacardio.2020.0652","journal-title":"JAMA Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.01.018","article-title":"Direct oral anticoagulants versus vitamin K antagonists for the treatment of left ventricular thrombi\u2014insights from a Swiss Multicenter Registry","volume":"194","author":"Seiler T","year":"2023","unstructured":"Seiler T, Vasiliauskaite E, Gr\u00fcter D, et al.. Direct oral anticoagulants versus vitamin K antagonists for the treatment of left ventricular thrombi\u2014insights from a Swiss Multicenter Registry. Am J Cardiol. 2023, 194:113-21. 10.1016\/j.amjcard.2023.01.018","journal-title":"Am J Cardiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097%2822%2901352-3","article-title":"Man agement and clinical outcomes of left ventricular thrombus","volume":"79","author":"Tamimi F","year":"2022","unstructured":"Tamimi F, Elmariah H, Patel Y, Omar A, Naoulou B, Fox JT, Kanei Y. Man agement and clinical outcomes of left ventricular thrombus. J Am Coll Cardiol. 2022, 79:361. 10.1016\/S0735-1097%2822%2901352-3","journal-title":"J Am Coll Cardiol"},{"key":"ref40","doi-asserted-by":"crossref","DOI":"10.11604\/pamj.2021.39.212.28585","article-title":"Treatment and outcomes in patients with left ventricular thrombus-experiences from the Aga Khan University Hospital, Nairobi-Kenya","volume":"39","author":"Varwani MH","year":"2021","unstructured":"Varwani MH, Shah J, Ngunga M, Jeilan M. Treatment and outcomes in patients with left ventricular thrombus-experiences from the Aga Khan University Hospital, Nairobi-Kenya. PAMJ. 2021, 39:1.","journal-title":"PAMJ"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1177\/1060028020975111","article-title":"Direct oral anticoagulants versus warfarin in the treatment of left ventricular thrombus","volume":"55","author":"Willeford A","year":"2021","unstructured":"Willeford A, Zhu W, Stevens C, Thomas IC. Direct oral anticoagulants versus warfarin in the treatment of left ventricular thrombus. Ann Pharmacother. 2021, 55:839-45. 10.1177\/1060028020975111","journal-title":"Ann Pharmacother"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-1683","article-title":"Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus","volume":"10","author":"Xu Z","year":"2021","unstructured":"Xu Z, Li X, Li X, Gao Y, Mi X. Direct oral anticoagulants versus vitamin K antagonists for patients with left ventricular thrombus. Ann Palliat Med. 2021, 10:9427-34. 10.21037\/apm-21-1683","journal-title":"Ann Palliat Med"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s12959-023-00488-1","article-title":"A prediction model for left ventricular thrombus persistence\/recurrence: based on a prospective study and a retrospective study","volume":"21","author":"Yang Q","year":"2023","unstructured":"Yang Q, Quan X, Wang C, Yu L, Yang Y, Zhu J, Liang Y. A prediction model for left ventricular thrombus persistence\/recurrence: based on a prospective study and a retrospective study. Thromb J. 2023, 21:50. 10.1186\/s12959-023-00488-1","journal-title":"Thromb J"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2024.10.042","article-title":"Comparison of direct oral anticoagulants and vitamin K antagonists for left ventricular thrombus: a global retrospective study","volume":"138","author":"Yao Z","year":"2025","unstructured":"Yao Z, Gue Y, Lip GY. Comparison of direct oral anticoagulants and vitamin K antagonists for left ventricular thrombus: a global retrospective study. Am J Med. 2025, 138:468-76. 10.1016\/j.amjmed.2024.10.042","journal-title":"Am J Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2022.12.003","article-title":"Apixaban in patients with post-myocardial infarction left ventricular thrombus: a randomized clinical trial","volume":"5","author":"Youssef AA","year":"2023","unstructured":"Youssef AA, Alrefae MA, Khalil HH, et al.. Apixaban in patients with post-myocardial infarction left ventricular thrombus: a randomized clinical trial. CJC Open. 2023, 5:191-9. 10.1016\/j.cjco.2022.12.003","journal-title":"CJC Open"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097%2820%2931575-8","article-title":"Direct oral anticoagulants are effective therapy in treating left ventricular thrombi","volume":"75","author":"Yunis A","year":"2020","unstructured":"Yunis A, Seese L, Stearns B, Genuardi M, Thoma F, Kilic A. Direct oral anticoagulants are effective therapy in treating left ventricular thrombi. JACC. 2020, 75:948. 10.1016\/S0735-1097%2820%2931575-8","journal-title":"JACC"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-021-01921-z","article-title":"Rivaroxaban versus vitamin K antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction","volume":"37","author":"Zhang Z","year":"2022","unstructured":"Zhang Z, Si D, Zhang Q, et al.. Rivaroxaban versus vitamin K antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction. Heart Vessels. 2022, 37:374-84. 10.1007\/s00380-021-01921-z","journal-title":"Heart Vessels"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-23-1582","article-title":"Direct oral anticoagulants compared with warfarin in patients with left ventricular thrombus: a cohort study from China","volume":"16","author":"Zhou Y","year":"2024","unstructured":"Zhou Y, Zhang X, Lin Y, Peng W. Direct oral anticoagulants compared with warfarin in patients with left ventricular thrombus: a cohort study from China. J Thorac Dis. 2024, 16:884-92. 10.21037\/jtd-23-1582","journal-title":"J Thorac Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2309312","article-title":"Direct oral anticoagulants versus vitamin K antagonists for the treatment of left ventricular thrombosis: a meta-analysis","volume":"23","author":"Li J","year":"2022","unstructured":"Li J, Hu Y, Wu Z. Direct oral anticoagulants versus vitamin K antagonists for the treatment of left ventricular thrombosis: a meta-analysis. Rev Cardiovasc Med. 2022, 23:312. 10.31083\/j.rcm2309312","journal-title":"Rev Cardiovasc Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14084","article-title":"Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus","volume":"9","author":"Huang L","year":"2022","unstructured":"Huang L, Tan Y, Pan Y. Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus. ESC Heart Fail. 2022, 9:3519-32. 10.1002\/ehf2.14084","journal-title":"ESC Heart Fail"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen S","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, et al.. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014, 35:1864-72. 10.1093\/eurheartj\/ehu046","journal-title":"Eur Heart J"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.01.057","article-title":"Antithrombotic therapy for patients with left ventricular mural thrombus","volume":"75","author":"Lattuca B","year":"2020","unstructured":"Lattuca B, Bouziri N, Kerneis M, et al.. Antithrombotic therapy for patients with left ventricular mural thrombus. J Am Coll Cardiol. 2020, 75:1676-85. 10.1016\/j.jacc.2020.01.057","journal-title":"J Am Coll Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a062374","article-title":"Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial infarction","volume":"8","author":"Johannessen KA","year":"1987","unstructured":"Johannessen KA, Nordrehaug JE, von der Lippe G. Left ventricular thrombi after short-term high-dose anticoagulants in acute myocardial infarction. Eur Heart J. 1987, 8:975-80. 10.1093\/oxfordjournals.eurheartj.a062374","journal-title":"Eur Heart J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1378\/chest.1412S3","article-title":"Execu tive summary: antithrombotic therapy and prevention of thrombosisAmerican college of chest physicians evidence-based clinical practice guidelines","volume":"141","author":"Guyatt GH","year":"2012","unstructured":"Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schu\u00fcnemann HJ. Execu tive summary: antithrombotic therapy and prevention of thrombosisAmerican college of chest physicians evidence-based clinical practice guidelines. Chest. 2012, 141:7S-47S. 10.1378\/chest.1412S3","journal-title":"Chest"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/365018-efficacy-and-safety-of-direct-oral-anticoagulants-versus-vitamin-k-antagonists-for-left-ventricular-thrombus-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:18:02Z","timestamp":1748416682000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/365018-efficacy-and-safety-of-direct-oral-anticoagulants-versus-vitamin-k-antagonists-for-left-ventricular-thrombus-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":54,"URL":"https:\/\/doi.org\/10.7759\/cureus.84941","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}